Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.


We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by Reaxense.


Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.


Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
Q16842

UPID:
SIA4B_HUMAN

ALTERNATIVE NAMES:
Gal-NAc6S; Gal-beta-1,3-GalNAc-alpha-2,3-sialyltransferase; Monosialoganglioside sialyltransferase; ST3Gal II; ST3GalA.2; Sialyltransferase 4B

ALTERNATIVE UPACC:
Q16842; O00654

BACKGROUND:
ST3Gal II, also known as Sialyltransferase 4B, is a key enzyme in the terminal sialylation of glycolipids, contributing to the formation of sialylated structures like SSEA4 from SSEA3. These sialylated glycoconjugates play critical roles in cell-cell communication, immune response modulation, and the maintenance of stem cell pluripotency. The enzyme's action is fundamental in the development and function of the central nervous system.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of ST3Gal II offers a promising pathway to novel therapeutic approaches. Given its crucial role in the sialylation processes that affect neural cell interactions, immune responses, and stem cell characteristics, targeting ST3Gal II could lead to breakthroughs in treating neurological disorders, enhancing regenerative medicine, and cancer therapy.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.